Adaptive Biotechnologies Corp. (ADPT)

24.92 -0.27 (-1.07%) USD  |  NASDAQ  |  Aug 31, 16:00
25.37 +0.45 (+1.81%) After-Hours: 20:00
More

Adaptive Biotechnologies Cash from Operations (Annual) : -45.99M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for ADPT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2017. Start Trial.
Date Value
December 31, 2025 -45.99M
December 31, 2024 -95.21M
December 31, 2023 -156.32M
December 31, 2022 -183.94M
December 31, 2021 -192.73M
Date Value
December 31, 2020 -149.68M
December 31, 2019 205.40M
December 31, 2018 -32.26M
December 31, 2017 -34.86M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Personalis, Inc. -74.95M
10X Genomics, Inc. 136.05M
Alamar Biosciences, Inc. (California) -53.61M
Champions Oncology, Inc. -4.472M
Medpace Holdings, Inc. 713.22M